Á, G., JM, P., M, R., B, B., M, G., J, d. l. H., . . . A, L. (2024). Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score =18: DxCARTES study.
Chicago Style CitationÁ, Guerrero-Zotano, et al. Neoadjuvant Letrozole and Palbociclib in Patients With HR-positive/HER2-negative Early Breast Cancer and Oncotype DX Recurrence Score =18: DxCARTES Study. 2024.
MLA CitationÁ, Guerrero-Zotano, et al. Neoadjuvant Letrozole and Palbociclib in Patients With HR-positive/HER2-negative Early Breast Cancer and Oncotype DX Recurrence Score =18: DxCARTES Study. 2024.
Warning: These citations may not always be 100% accurate.